GlassScriptPhysician profile
Jeffrey C Nascimento
NPI 1235256934
$212,830.14
in general payments reported to CMS, 2019-2025
38 companies · $7,605 in 2025
The $7,605 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $14K · 2021: $27K · 2022: $18K · 2023: $80K · 2024: $47K · 2025: $7,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Food and Beverage: $9,735 · Honoraria: $4,726 · Travel and Lodging: $1,561 · Education: $81.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,975.00 |
| Food and Beverage | $9,734.78 |
| Honoraria | $4,725.50 |
| Travel and Lodging | $1,561.39 |
| Education | $81.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $181,542.03 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,964.24 | 2019-2025 | Jascayd, Ofev |
| Axsome Therapeutics, INC. | $4,965.49 | 2023-2025 | Sunosi, Auvelity |
| Astrazeneca Pharmaceuticals LP | $3,446.81 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Harmony Biosciences LLC | $888.40 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $690.10 | 2019-2025 | |
| Mylan Specialty L.P. | $564.00 | 2019-2023 | Yupelri |
| Amgen INC. | $411.98 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $410.27 | 2019-2025 | Dupixent |
| Electromed, INC. | $313.47 | 2024-2025 | Smartvest |
| Verona Pharma, INC. | $305.14 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $255.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $243.82 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $226.51 | 2023-2025 | Lumryz |
| Janssen Pharmaceuticals, INC | $219.36 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nascimento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.